Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet. by Cravens, Petra D et al.
UCSF
UC San Francisco Previously Published Works
Title
Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive 
transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet.
Permalink
https://escholarship.org/uc/item/1312b8tv
Journal
Journal of neuroinflammation, 8(1)
ISSN
1742-2094
Authors
Cravens, Petra D
Hussain, Rehana Z
Zacharias, Tresa E
et al.
Publication Date
2011-06-24
DOI
10.1186/1742-2094-8-73
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH Open Access
Lymph node-derived donor encephalitogenic
CD4+ T cells in C57BL/6 mice adoptive transfer
experimental autoimmune encephalomyelitis
highly express GM-CSF and T-bet
Petra D Cravens1, Rehana Z Hussain1, Tresa E Zacharias1, Li-Hong Ben1, Emily Herndon2, Ramya Vinnakota,
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Abstract
Experimental autoimmune encephalomyelitis (EAE) is a relevant animal model for the human demyelinating
inflammatory disorder of the central nervous system (CNS), multiple sclerosis (MS). Induction of EAE by adoptive
transfer allows studying the role of the donor T lymphocyte in disease pathogenesis. It has been challenging to
reliably induce adoptive transfer EAE in C57BL/6 (H-2b) mice. The goal of this study was to develop a reproducible
and high yield protocol for adoptive transfer EAE in C57BL/6 mice. A step-wise experimental approach permitted
us to develop a protocol that resulted in a consistent relatively high disease incidence of ~70% in recipient mice.
Donor mice were immunized with myelin oligodendrocyte glycoprotein (MOG)p35-55 in complete Freund’s adjuvant
(CFA) followed by pertussis toxin (PT). Only lymph node cells (LNC) isolated at day 12 post immunization, and
restimulated in vitro for 72 hours with 10 μg/mL of MOGp35-55 and 0.5 ng/mL of interleukin-12 (IL-12) were able to
transfer disease. The ability of LNC to transfer disease was associated with the presence of inflammatory infiltrates
in the CNS at day 12. Interferon gamma (IFNg) was produced at comparable levels in cell cultures prepared from
mice at both day 6 and day 12 post immunization. By contrast, there was a trend towards a negative association
between IL-17 and disease susceptibility in our EAE model. The amount of GM-CSF secreted was significantly
increased in the culture supernatants from cells collected at day 12 post immunization versus those collected at
day 6 post-immunization. Activated CD4+ T cells present in the day 12 LNC cultures maintained expression of the
transcription factor T-bet, which has been shown to regulate the expression of the IL-23 receptor. Also, there was
an increased prevalence of MOGp35-55-specific CD4
+ T cells in day 12 LNC after in vitro re-stimulation. In summary,
encephalitogenic LNC that adoptively transfer EAE in C57BL/6 mice were not characterized by a single biomarker
in our study, but by a composite of inflammatory markers. Our data further suggest that GM-CSF expression by
CD4+ T cells regulated by IL-23 contributes to their encephalitogenicity in our EAE model.
1. Introduction
Multiple sclerosis (MS) is an inflammatory-mediated
demyelinating disease of the human central nervous
system (CNS) that afflicts approximately 2.5 million
individuals worldwide [1]. Experimental autoimmune
encephalomyelitis (EAE) is the most commonly used
animal model for studying the underlying disease
mechanisms of MS and for testing potential new thera-
pies [2-4]. Two methods are commonly used to induce
EAE in rodents: (1) Active immunization and (2) adop-
tive transfer [2,4]. In active immunization, the experi-
mental animal is inoculated with the encephalitogenic
antigen in Complete Freund’s Adjuvant (CFA) or other
adjuvants. In addition, the administration of pertussis
toxin (PT) is required for disease induction in many
mouse strains. Following immunization with a dominant
determinant, numerous immune competent cells* Correspondence: olaf.stuve@utsouthwestern.edu1Department of Neurology, University of Texas Southwestern Medical Center
at Dallas, TX, USA
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undergo activation, including antigen presenting cells
(APC) and effector cells.
The adoptive transfer model was developed to specifi-
cally test the role of antigen specific T cells in EAE patho-
genesis [5-7]. For this purpose, donor mice are immunized
with antigen in CFA, and their lymph nodes (LNs) or
spleens are harvested 6-14 days later. Single cell suspen-
sions are prepared from the harvested organs, and are re-
stimulated in vitro with antigen and cytokines to select for
a population of antigen-specific encephalitogenic T cells.
After 3-8 days of culture, the cells are injected into recipi-
ent mice. In susceptible mouse strains, disease onset and
disease severity can parallel that of EAE following active
immunization.
While EAE induction by adoptive transfer is reliable and
reproducible in several mouse strains [8-10], adoptive
transfer in the C57BL/6 model (H-2b) has been proble-
matic in our hands and in the hands of other investigators
(personal communications). Specifically, disease incidence,
time of disease onset, and disease severity after transfer of
myelin oligodendrocyte glycoprotein peptide (MOGp)35-55-
specific T cells are highly variable. Pre-conditioning of
recipients with sub-lethal irradiation can be an additional
confounding factor in the pathogenesis of CNS demyeli-
nating disease. Overall, the C57BL/6 mouse is considered
relatively resistant to EAE induction by adoptive transfer.
The C57BL/6 mouse is of particular interest to neuroim-
munologists and neuroscientists for numerous reasons: (1)
It is now the most commonly used mouse strain in
actively induced EAE experiments; (2) most genetically-
modified mouse strains are on the C57BL/6 background;
(3) C57BL/6 mice are commonly backcrossed with trans-
genic mice or gene-deficient mice on the C57BL/6 back-
ground. Therefore, successfully inducing EAE in the
C57BL/6 mouse via adoptive transfer is critical for study-
ing the contribution of encephalitogenic T cells in clinical
and paraclinical CNS autoimmune disease.
In this project, we identified and characterized a reli-
able and reproducible method of adoptively transferring
EAE into immunocompetent C57BL/6 mice.
2. Materials and methods
2.1 Immunizing donor mice
C57BL/6 donor mice were purchased from (The Jackson
Laboratories, Bar Harbor, MN) and bred at the University
of Texas Southwestern Medical Center (UTSW) under
specific pathogen free conditions. All animal protocols
were approved by the UTSW Institutional Animal Care
and Use Committee (IACUC). Donor mice were anesthe-
tized with tribromoethanol (®Avertin; Sigma Aldrich, St.
Louis, MO) 250 mg/kg intraperitoneally (i.p.) and then
immunized subcutaneously (s.c.) with a homogenized
emulsion of 200 μg/100 μL MOGp35-55 (C.S. Bio, Menlo
Park, CA)/Complete Freund’s Adjuvant (CFA)(DIFCO
Laboratories, Detroit, Michigan, USA) supplemented
with 2 mg/ml of mycobacterium tuberculosis H37RA
(MT) (DIFCO Laboratories). 25 μl of emulsion was
injected into the bilateral scapular and inguinal areas. In
some experiments, the donor mice or the recipient mice
were also injected i.p. with 200 ng/200 μL pertussis toxin
(PT) (List Biological Laboratories Inc)/phosphate buf-
fered saline (PBS) (Sigma Aldrich, St. Louis, MO) on the
day of immunization and 2 days post immunization.
2.2 Preparing single cell suspensions
Lymph nodes cells (LNC) and splenocytes (SPC) were har-
vested from donor mice at 6 or 12 days post immunization
(Figure 1). Organs were pressed through a 70 μm mesh
into cold PBS. Cells were pelleted at 450g for 5 minutes at
4°C. SPC and LNC were resuspended in red blood cell lys-
ing buffer (Sigma, St. Louis, MO) for 5 minutes. After
three washes in with cold PBS, cells were counted with the
hemocytometer. For counting, cells were diluted with 0.4%
Trypan Blue (Sigma Aldrich, St. Louis, MO) to permit dis-
crimination of dead cells.
2.3 Preparation of donor cells for adoptive transfer
LNC and SPC were cultured for 3-7 days in 75 ml tissue
culture flasks (Corning, Corning, NY) at 7.5 million cells/
mL in RPMI 1640 supplemented with 10% fetal bovine
serum (FBS), 1.25% Hepes buffer,1% sodium pyruvate, 1%
penicillin-strepyomycin, 1% glutamine, 1% non essential
amino acids, 0.01% 0.05m-2 mercaptoethanol (2-ME)
(Sigma Aldrich, St. Louis, MO). Cells were cultured with
either 10 or 20 μg/mL of MOGp35-55. Also, cells were cul-
tured with one of two cytokines: Interleukin-2 (IL-2)
(R&D Systems, Minneapolis, MN) at 10 μg/mL or inter-
leukin-12 (IL-12) (R&D Systems, Minneapolis, MN) at
0.5 ng/mL. For some experiments, cells were cultured in
24 well plates (Corning, Corning, NY) at 1 × 106 - 2 × 106
cells/well at 1 × 106 cells/mL in complete RPMI. Before
adoptive transfer into recipient mice, cell viability was
assessed by trypan blue exclusion.
2.4 Histology
Brains and spinal cords from naïve and immunized mice
were collected into 10% formalin. Tissues were
embedded in paraffin and sections were stained with
H&E to detect immune cell infiltration, PAS to deter-
mine the presence of myelin breakdown products, and
with Luxol Fast Blue to examine demyelination as
described [11,12]. Tissues were scored by a blinded
examiner.
2.5 Induction of EAE by Adoptive transfer
After 3-7 days of culture, the LNC and SPC were
washed twice with room temperature PBS and 1 × 107 -
2 × 107 cells/200 μL PBS were injected i.p. into recipient
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Figure 1 General schematic for induction of EAE by adoptive transfer into C57BL/6 mice. Groups of donor mice were immunized with
CFA/(MOG)35-55. Some mice also received pertussis toxin (PT) on the day of immunization (day 0) and on day 2 post immunization. Lymph node
cells (LNC) and splenocytes SPC) were harvested at either day 6 or day 12 post immunization and were restimulated in vitro with a combination
of MOGp35-55 and IL-2, or MOGp35-55 and IL-12 for 3-8 days in tissue culture flasks. After specified days in culture, 10-20 × 10
6 cells in 200 μL PBS
were injected into recipient mice. Mice were observed every day after injection for disease onset and clinically scored.
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male C57BL/6 mice. The mice were monitored daily for
onset of EAE.
2.6 Clinical scoring
EAE was evaluated and scored according to following
criteria: 0-no clinical abnormality; 0.5-limp tail only;
1-limp tail with mild hindlimb weakness; 2-limp tail
with moderate hindlimb weakness; 3-hindleg paresis
with or without mild forelimb weakness; 4-hindleg par-
esis with or without moderate forelimb weakness;
5-quadriplegia; and 6-dead or moribund [11-16].
2.7 Cytokine Analysis
Cytokines present in the cell culture supernatants of
LNC and SPC harvested on Day 6 and Day 12 post
immunization with MOG/CFA and restimulated in vitro
for 72 hours in the presence of MOGp35-55 and IL-12,
were quantified using the Cytometric Bead Array (CBA)
kit for IFN-g, Il-17 and GM-CSF (BD Biosciences). Data
were acquired on a LSRII instrument (BD Biosciences,
San Jose, CA) and analyzed using the BD Flowcap data
analysis software.
2.8 Flow cytometry
For intra-cellular cytokine staining, LNC and SPC were sti-
mulated with PMA (50 ng/ml) and ionomycin (750 ng/ml)
directly ex-vivo at day 6 and day 12 post-immunization.
GolgiPlug (1 μl/ml) was added to each well. After 5 hours
stimulation, cells were collected, washed, and resuspended
in staining buffer (4% FCS and 0.1% sodium azide in PBS).
Fc receptors were blocked with anti-CD16/32, and the cell
surface was stained with the following mAb: Anti-CD3,
anti-CD4 (Invitrogen), anti-CD8 (ebioscience, San Diego,
CA), and antiCD62L and anti-CD44 (BD Biosciences)
mAbs for 30 min at 4°C. After washing twice with staining
buffer, cells were fixed and permeabilized using Cytofix/
Cytoperm solution (BD Biosciences) for 20 min at 4°C.
Intracellular cytokines were detected with anti-IFNg mAb
and anti-IL-17 diluted in PermWash solution for 30 min at
4°C. Cells were washed, resuspended in staining buffer, and
fixed in 1% paraformaldehyde. Fifty thousand to 100,000
CD4+ events were acquired on the FACSAria (BD Bios-
ciences) using the Diva Software package. Data was ana-
lyzed using FlowJo software (Tree Star, Ashland, OR).
CD3+ CD4+ CD44+T lymphocytes were examined for
expression of IFNg and IL-17.
Expression of T-bet by LNC and SPC that were to be
adoptively transferred into recipient mice, was examined
by flow cytometry as previously described (Gocke et al J.
Immunol 2007). Briefly, after the cell surface was stained
as described above, cells were washed and incubated with
Fixation/Permabilization buffer (ebioscience) for 1 hour
at 22°C. After washing twice in Permeabilization buffer
(ebioscience) cells were stained for 60 minutes at 22°C
with PE conjugated anti-T-bet (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) or isotype control Ab diluted in
Permeabilization buffer. Cells were washed twice in per-
meabilization buffer and at least 50,000 CD4+ events
were collected on a FACSAria (BD Biosciences, San Jose,
CA). Data was analyzed as described above.
For MOG MHC class II tetramer staining, cultured LNC
and SPC prepared for adoptive transfer were stained with
fluorochrome labeled antibodies against murine CD3,
CD4, and CD44 (BD Biosciences, San Jose, CA), and
MOG38-49 MHC class II tetramer or control MHC class II
tetramers containing hCLIP103-117 (both tetramers were
generously provided by the NIH Tetramer Core Facility).
After the cells were stained, samples were acquired on a
FACSAria flow cytometer (BD Biosciences) and the data
analyzed using Flowjo software (Treestar, Ashland, OR).
Cells were gated for live cells and then CD3+ CD4+ CD44+
T lymphocytes were examined for tetramer reactivity.
Cells that were MOG tetramer-positive and CD44+ were
considered MOG-specific and thus recently activated.
2.9 Statistical analysis
Every experiment was repeated at least once. Error bars
represent SEM. The means of two normally distributed
samples were compared by Student’s t-test. A minimum
of 4 experimental animals was included in each para-
digm. P-values < 0.05 were considered significant.
3. Results
3.1 LNC but not SPC isolated from C57BL/7 donors on
day12 post immunization and with PT were able to
transfer disease into C57BL/6 recipients after 72 hour in
vitro restimulation with myelin antigen and IL-12
There were numerous combinations of biological factors
that have been implicated in encephalitogenicity of T cells
in other commonly used strains of mice [8-10,17]. To test
these combinations in C57BL/6 mice, our experiments
were set up as shown in the schematic diagram in Figure 1.
Multiple experimental paradigm that yielded negative
results are outline below but not shown in Figure 1. SPC of
C57BL/6 donors that had been treated with PT or not, did
not lead to disease induction in recipient mice regardless
of the culture condition tested (data not shown). Similarly
to SPC, LNC of mice that had been treated with PT or not,
6 days after inoculation with MOGp35-55 did not transfer
disease. In vitro treatment of day 6 donor cells with IL-2
during the culture period prior to adoptive transfer did not
result in EAE in any of the recipient animals. PT injections
of the recipient had no effect on disease incidence (data
not shown). In one set of experiments, we tested whether
an antigen-specific or non-antigen-specific inflammatory
challenge would increase the encephalitogenic potential of
adoptively transferred cells under otherwise suboptimal
conditions. Incomplete Freund’s adjuvant (IFA)/MOGp35-
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55, or IFA/ovalbumin (OVA), or IFA/proteolipid protein
(PLP)178-191, or lipopolysaccharide (LPS) were administered
to mice on day 24 post adoptive transfer of LNC obtained
from PT-treated donor mice 12 days post inoculation with
MOGp35-55, and cultured for 72 hours in the presence of
antigen and IL-2. None of the recipient mice developed
clinical signs of EAE (data not shown).
Of all of the combinations tested only one resulted in
the ability to adoptively transfer EAE into C57BL/6 as
shown in (Figure 2). The successful protocol required
LNC that were harvested from donor mice that had
been immunized 12 days previously and had been trea-
ted with PT. Following LNC isolation, the cells were
restimulated in vitro with MOGp35-55 (10 μg/ml) and IL-
12 (0.5 ng/ml) for 72 hours. At this timepoint, LNC but
not SPC were able to induce EAE in recipient mice
The CNS of donor mice was examined histologically
to determine if the different immunization paradigms
would result in an influx of leukocytes into the CNS,
suggesting the generation of encephalitogenic CD4+ T
cells. Inflammatory infiltrates could be identified in sec-
tions of donor brain and spinal cord at day 12 but not
in donor mice at day 6 post-immunization (Figure 3A,
B, C, D, E, G, &3I), Table 1). Also at day 12 post immu-
nization, but not on day 6 post immunization, there was
PAS positive material throughout the CNS without
detectable areas of demyelination (Figure 3 F, H, &3J).
3.2 Determining cytokine secretion by in vivo polarized T
lymphocytes
The successful induction of disease following the adop-
tive transfer of day 12 LNC as described above, and the
detection of inflammatory CNS infiltrates in donor mice
12 days after immunization, we hypothesized that the
production of proinflammatory cytokines is associated
with the ability of the day 12 LNC, but not other cells,
to transfer disease in C57BL/6 mice. LNC and SPC
from donor mice immunized 6 or 12 days previously
were stimulated directly ex-vivo to determine the fre-
quency of recently activated CD3+CD4+CD44+ T cells
present in these tissues prior to in vitro restimulation
with antigen. A comparable number of IFNg and Il-17
expressing T cells were detected in both LNC and SPC
at day 6 and day 12 (Figure 4 B, D, F, &4H).
3.3 Determining in vitro cytokine expression in LNC and
SPC prior to adoptive transfer
To further define the cellular phenotype of donor cells
prior to adoptive transfer in the paradigm that confers
disease in C57BL/6 mice, LNC and SPC were
DDDD12
D12 LNC
All other exp
paradigms
Figure 2 EAE disease course in C57BL/6 mice after adoptive transfer of day 12 LNC. The successful protocol required LNC that were
harvested from donor mice that had been immunized 12 days previously and had been treated with PT. Following LNC isolation, the cells were
restimulated in vitro with MOGp35-55 (10 μg/ml) and IL-12 (0.5 ng/ml) for 72 hours. Error bars represent ± SD. Clinical scores shown are from at
least two independent experiments. The difference between the successful experimental paradigm (●)and all unsuccessful paradigms (O) with
regard to disease activity was significant, starting on day 7 (p ≤ 0.001).
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Figure 3 Histopathological examination of the CNS of donor mice. Representative data on the inflammatory infiltrates in the brain and
spinal cord on day 12 are shown. A. Cerebellar cortex. B. Lateral brainstem. C. Posterior colliculus. D. Ventral brainstem. E. H&E and F. LFB/PAS/
H&E of spinal cord dorsal root. G. H&E and H. LFB/PAS/H&E of lateral spinal cord white matter. I. H&E and J. LFB/PAS/H&E of ventral spinal cord
white matter.
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restimulated on day 6 or day 12 in vitro for 72 hours in
the presence of MOGp35-55 and IL-12. At this timepoint,
cell culture supernatants were collected and the levels of
IFNg, IL-17 and GM-CSF were determined using cyto-
kine bead arrays. IFNg was produced at comparable
levels in cell cultures prepared from mice at both day 6
and day 12 post immunization (Figure 5A). By contrast,
there was a trend towards a negative association
between IL-17 and disease susceptibility in our EAE
model (Figure 5B). The amount of GM-CSF secreted
was significantly increased in the culture supernatants of
cells collected at day 12 post immunization versus those
collected at day 6 post-immunization (Figure 5C).
3.4 Determining the levels of T-bet expression in cell
populations to be adoptively transferred
Expression of the transcription factor T-bet has been
shown to play an important role in the development of
encephalitogenic T cells [18-21]. To determine the ence-
phalitogenic potential of the donor restimulated LNC
and SPC to be adoptively transferred, we used flow cyto-
metry to evaluate expression of T-bet. Cells from both
day 6 and day 12 donor mice were restimulated in vitro
for 72 hours with MOGp35-55 and IL-12. While we were
able to detect CD44+T-bet+ CD4+ T cells in all culture
conditions tested (Figure 6B, D, F, &6H), the frequency
of CD44+T-bet+ CD4+ T cells was substantially higher
in the day 12 LNC (Figure 6D), the only cells which
were able to transfer disease into C57BL/6 mice.
3.5 Determining MOG-specificity in donor LNC and SPC
In order to determine the frequency of MOGp35-55-spe-
cific T cells present within the population of donor cells
to be adoptively transferred into recipient mice, MOG38-
49 tetramer staining was performed on LNC and SPC
collected from donor mice that had been immunized
with MOGp35-55/CFA 6 days or 12 days previously.
When CD3+ CD4+ CD44+ T lymphocytes were stained
after 72 hours of culture in the presence of MOGp35-55
and IL-12, a substantial number of MOGp35-55-specific
CD4+ T cells were detected in day and day 12 LNC,
and day 12 SPC (Figure 7 B, F, &7H).
4. Discussion
In a systematic, step-wise approach, we identified a
paradigm that leads to reliable and reproducible induc-
tion of EAE by adoptive transfer in C57BL/6 mice, a
mouse strain that is widely considered relatively disease
resistant to this method of EAE induction. We made
several interesting observations that led to the develop-
ment of this experimental approach.
We observed that PT injections of the donor mice
were required for successful adoptive transfer of EAE
into C57BL/6 mice. PT treatment of recipient mice had
no apparent effect on disease susceptibility. PT is predo-
minantly used as an adjuvant for EAE disease induction
by active immunization. Traditionally it was thought
that PT disrupts the blood-brain barrier (BBB) by ampli-
fying an inflammatory antigen-specific autoimmune
response [22]. Other proposed mechanisms of PT in
EAE disease induction include; the prevention of anergy,
the induction of autoantigen-specific T cells [23], the
abrogation of T-cell tolerance [24], and the irreversible
inhibition of G proteins and other second messengers
than may affect signaling pathways in the T cell or the
APC that regulates T-cell differentiation [25]. In this
regard, Shive and coworkers demonstrated that PT sti-
mulates APCs resulting in the differentiation of T helper
cells towards a Th1 phenotype [26]. More recently, Hof-
stetter and colleagues showed that co-injection with PT
during active immunization activates APCs in the per-
ipheral lymphoid organs and the CNS by inhibiting sig-
naling through G proteins rather than signaling through
Toll-like receptors [27]. In the adoptive transfer model
of EAE, the transferred antigen-specific encephalitogenic
T cell is less dependent on reactivation in CNS than in
the active immunization model but interaction with
DCs in the perivascular spaces and meninges is neces-
sary for the entry of encephalitogenic T cells into the
CNS parenchyma [28]. Our data suggest that PT treat-
ment of the donor alone is sufficient to promote an
encephalitogenic T cell phenotype that when transferred
into healthy C57BL/6 recipients can result in the devel-
opment of EAE.
With regard to cytokine expression by T cells to be
adoptively transferred we focused on IFNg, IL-17, and
GM-CSF. In the past two decades, TH1 cells that
express IFNg, tumor necrosis factor beta (TNF)-ß, IL-2,
and nitric oxide [29] have been implicated in EAE
pathogenesis. IFNg is considered the signature cytokine
of TH1 cells, which activate myeloid cells to promote
cell-mediated immunity. Perhaps the most convincing
evidence to support a pathogenic role of IFNg in CNS
Table 1 Presence of inflammatory infiltrates (+) or not (-)
in the CNS of naïve and donor C57BL/6 mice at day 6 or
day 12 post-immunization with CFA/MOGp35-55 plus PT
treatment
Naive Day 6 Day 12
Cerebellar cortex - - +
Lateral brainstem - - +
Posterior colliculus - - +
Ventral brainstem - - +
Spinal cord dorsal root - - +
Lateral spinal cord white matter - - +
Ventral spinal cord white matter - - +
Tissues were processed for histopathological evaluation as described in the
material and methods section.
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Figure 4 Determining cytokine secretion by in vivo polarized T lymphocytes. LNC and SPC from donor mice immunized 6 or 12 days
previously were stimulated directly ex-vivo with PMA (50 ng/ml) and ionomycin (750 ng/ml) to determine the frequency of recently activated
CD3+CD4+CD44+ T cells present in these tissues prior to in vitro restimulation with antigen. IFNg and Il-17 expressing T cells in LNC and SPC at
day 6 and day 12 are shown in panels B, D, F, and H. Isotype controls are shown in panels A, C, E, and G. Data are representative of at least
three independent experiments.
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Figure 5 Cytokine production in vitro. LNC and SPC harvested from donor mice at day 6 and day 12 post-immunization were cultured in vitro
with 10 μg/ml MOG35-55 with 0.5 ng/ml IL-12. The concentration of IFN-g (A), IL-17 (B), and GM-CSF (C) secreted by spleen and LNC after 72
hours in culture was determined by cytokine bead array (CBA). Data shown are representative of at least 2 independent experiments. ns = not
significant.
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Figure 6 Flow cytometry analysis of expression of T-bet by encephalitogenic CD4+ T cells is maintained in Day 12 LNC. C57BL/6 donor
mice were immunized with CFA/MOGp35-55 followed by PT at day 0 and day2. At day 6 or day 12, LNC and SPC were harvested and cultured
for 72 hours in the presence of MOGp35-55 and IL-12 and prepared for flow cytometry. CD3
+CD4+CD44+ T cells were examined for expression of
T-bet. The percentage of T-bet+ cell is indicated in the quadrants B, D, F, & H. Isotype controls are shown in panels A, C, E, and G. Data shown
are representative of at least 3 independent experiments.
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Figure 7 Determining MOG-specificity in donor LNC and SPC. At day 6 or day 12, LNC and SPC were harvested and cultured for 72 hours in
the presence of MOGp35-55 and IL-12 and prepared for tetramer staining. CD3
+CD4+CD44+ T cells were examined for staining with MOG38-49
MHC class II tetramer, or control MHC class II tetramers containing hCLIP103-117. The percentage of MOG38-49 MHC class II tetramer positive cell is
indicated in the regions B, D, F, & H. Control MHC class II tetramers containing hCLIP103-117 staining is shown in panels A, C, E, and G. Data
shown are representative of at least 3 independent experiments.
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autoimmune disease was derived from an open-label,
randomized clinical trial, in which 18 patients with MS
received 1 μg, 30 μg, or 1000 μg of recombinant IFNg
i.v. twice a week for four weeks [30]. During treatment,
7 patients experienced an exacerbation. The trial investi-
gators also detected an increase in circulating mono-
cytes bearing major histocompatibility complex (MHC)
II surface antigen, suggesting that clinical attacks during
treatment were immunologically mediated. Interestingly,
studies performed in IFNg deficient mice or in mice
treated with anti-IFNg mAb developed more severe EAE
[31-34]. Therefore the contribution of IFNg to EAE
pathogenesis remains unclear. We were able to detect
both IFNg in cell culture supernatants in all experimen-
tal paradigms, suggesting that TH1 cells were present in
the adoptively transferred cells. Our data suggest that
IFNg expression by T cells is not sufficient for encepha-
litogenicity in this EAE model.
More recently, TH17 cells were identified as a distinct
lineage of CD4+ T helper cells that may facilitate the
initiation and perpetuation of CNS autoimmune diseases
[35]. TH17 cells synthesize IL-17, which mediates proin-
flammatory and allergic responses. The role of IL-17 as a
causal factor in the etiology of EAE has remained some-
what controversial as mice deficient in IL-17 can develop
EAE [32,36-40]. In our model of adoptive transfer and in
the C57BL/6 mouse strain it appears that high expression
of IL-17 by transferred donor cells is not absolutely
required for disease induction. Furthermore, high expres-
sion of IL-17 by adoptively transferred day 6 LNC is not
sufficient to induce CNS autoimmune disease. However,
adoptive transfer EAE may be a multi-phasic disease.
O’Connor et al recently showed in a C57BL/6 adoptive
transfer model that purified antigen-specific TH1 cells are
highly pathogenic, whereas transfer of purified TH17 cells
does not cause disease [39]. Activated TH1 cells could
readily access the non-inflamed CNS of recipient mice,
whereas TH17 cells only appear in the CNS of mice with
established EAE. These data and our own observations
suggest that a high number of TH17 donor cells may not
be required for disease induction, but may be critical to
sustain CNS inflammation. TH17 cells may be recruited
from the host during the amplification of the initial
inflammatory response.
Other investigators recently showed that GM-CSF
may play critical role in different models of active and
passive EAE [41-43]. Our own results indicated that
GM-CSF is secreted by LNC and SPC after antigen re-
stimulation in the presence of IL-12. While GM-CSF
was highly expressed by day 12 encephalitogenic LNC in
our EAE model, it was also highly expressed by day 12
non-encephalitogenic SPC.
The transcription factor T-bet has recently been
shown to be critical for encephalitogenicity [20,21]. Its
precise role in EAE and MS pathogenesis remains to be
fully elucidated. T-bet has pleiotropic biological effects,
among one of which is the regulation of expression of
the IL-23 receptor [21,44]. In turn, IL-23 was recently
shown to regulate the expression of GM-CSF by CD4+
Tcells [42]. When we analyzed both splenocytes and
LNC for expression of T-bet immediately before transfer
into recipient mice, we found that T-bet+ cells were
maintained in the day 12 LNC, the only cell population
able to transfer EAE. While T-bet+ cells were present in
the CD4+ populations of the day 6 splenocytes and
LNC, as well as day 12 splenocytes, these cells failed to
transfer EAE.
In summary, we have identified an algorithm that
leads to a reproducible induction of adoptive transfer
EAE in C57BL/6 mice. There was no single biomarker
associated with donor T cell encephalitogenicity.
Instead, adoptively transferred day 12 LNC have the
potential of reproducibly inducing EAE in the C57BL/6
mice are characterized by a composite of inflammatory
markers that include the expression of GM-CSF and T
bet. Our data further suggest that GM-CSF expression
by CD4+ T cells regulated by IL-23 contributes to their
encephalitogenicity in our EAE model. Finally, there was
an increased prevalence of MOGp35-55-specific CD4
+ T
cells in day 12 LNC after in vitro re-stimulation. Our
protocol is currently being verified in genetically-modi-
fied mice on the C57BL/6 background.
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